For example, Hu5F9-G4, a monoclonal antibody against CD47, has demonstrated promising results in early-phase clinical trials for the treatment of Acute Myeloid Leukemia (AML) and non-Hodgkin lymphoma. The gene discussed is CD47; the disease is acute myeloid leukemia.